1331908-02-1
1331908-02-1
Chemical Structure
Valsartan-d3
Synonym(s): CGP 48933-d3
- CAS No.: 1331908-02-1
- Formula:C24H26D3N5O3
- Molecular Weight:438.54
IUPAC Name: N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-(pentanoyl-5,5,5-d3)-L-valine
InChIKey: ACWBQPMHZXGDFX-MVTYLIICSA-N
SMILES: CC(C)[C@@H](C(O)=O)N(C(CCCC([2H])([2H])[2H])=O)CC1=CC=C(C=C1)C2=C(C3=NN=NN3)C=CC=C2
Biological Activity: Valsartan-d3 is the deuterium labeled Valsartan[1]. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Valsartan-d3 | 94.36% | Valsartan-d3 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valsartan (Standard) | 99.95% | Valsartan (Standard) is the analytical standard of Valsartan. This product is intended for research and analytical applications. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Valsartan-d9 | (Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valsartan-d9 | 99.33% | Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valsartan-d8 | 99.59% | Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valsartan | 99.97% | Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Shan H, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014 Jun;18(6):1071-80. [Content Brief]
